Health
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosisSAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplifie
About this update from Resmed Inc.
[{"type":"image","alt":"Resmed, Inc.","displaySize":"","headline":null,"caption":"Resmed, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/730e54661ce751c82be107ad83b26aa1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ySxRVVDtobnI_Tbqb.mpyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/730e54661ce751c82be107ad83b26aa1","width":300,"height":63}},"lazy":false},{"type":"text","content":"FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis","length":122,"tagName":"p"},{"type":"text","content":"SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual’s home.","length":492,"tagName":"p"},{"type":"text","content":"OSA, a sleep disorder where breathing repeatedly stops during sleep due to blocked upper airways, affects nearly one billion people globally1, yet approximately 80% of cases remain undiagnosed and untreated2. Additionally, a recent study published in The Lancet Respiratory Medicine found that treating OSA with CPAP therapy can significantly reduce the risk of death3 - underscoring the importance of accessible and simplified diagnostic options. NightOwl makes it easy to detect OSA with a small sensor worn on the fingertip and simple, easy-to-use digital platforms for both individuals and providers. By making OSA testing more convenient and accessible, NightOwl supports Resmed’s vision to help people achieve their full potential through better sleep and breathing, with care delivered in their own home.","length":811,"tagName":"p"},{"type":"text","content":"“Now more than ever, people want healthcare experiences that are easy, convenient, and accessible, however, navigating sleep apnea testing can be complex,” said Carlos M. Nunez, M.D., Chief Medical Officer at Resmed. “With NightOwl, people can easily complete a s...